Global 
Australia 
België 
Deutschland 
España 
France 
Ireland 
Italia 
Luxembourg 
Nederland 
Österreich 
Portugal 
Россия 
Schweiz 
United Kingdom 
Последние новости от компании Др. Фальк Фарма
Добро пожаловать на нашу страницу новостей, где предоставлены последние новости, пресс-релизы, аннонсы клинических исследований, информация о мероприятиях и многое другое от компании Др. Фальк Фарма.
Strategic Partnership with Allianthera (Suzhou) Biopharmaceuticals
for Novel AhR Agonist Development for the Treatment of Moderate to Severe Ulcerative Colitis
Completion of Enrollment of the Global Phase 2b Study
... Evaluating Naronapride in Gastroparesis (MOVE-IT)
Positive results from pivotal phase 3 trial on norucholic acid in PSC
The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam
Burden of disease of Primary Sclerosing Cholangitis
A Retrospective Cohort Study in Germany
Dr. Falk Pharma acquires Kynos Therapeutics
...adding acute pancreatitis as a therapeutic focus and further strengthening its development portfolio
Following the footsteps of our founder
Herbert Falk's granddaughter Elena decided to follow her grandpa's footsteps. Why? Find out more and follow Elena on her journey.
EASL 2024
From 5-8 June 2024 in Milan - we look forward to seeing you (exhibition space E2)
FDA clearance of IND application for naronapride
...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US
Advancing the development of naronapride...
...for patients with PPI-non-responsive symptomatic GERD as the second naronapride indication
